Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981045 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
A Phase 3 study of Iron Deficiency Anemia and Impaired Renal Function, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,561
- Enrollment target
- 1
- Study location
NCT00981045: Completed Phase 3 study of Iron Deficiency Anemia and Impaired Renal Function, sponsored by American Regent.
NCT00981045 is a Phase 3 study of Iron Deficiency Anemia and Impaired Renal Function that has completed, run by American Regent. The registered enrollment target is 2,561 participants, above the 87-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (2844% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00981045, a Phase 3 study of Iron Deficiency Anemia and Impaired Renal Function, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,561 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to examine the efficacy and safety (cardiovascular) of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron sucrose (Venofer) in subjects who have iron deficiency anemia (IDA) and impaired renal function.
Conditions Studied
Interventions
- DRUG Ferric Carboxymaltose (FCM)
- DRUG Iron Sucrose (Venofer)
Study Locations (1)
Pennsylvania
- Luitpold Pharmaceuticals, Inc. - Norristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,561 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
What the finished NCT00981045 record still lists
NCT00981045 is an interventional study that assigns participants to a tested intervention. Its 2,561 participants enrollment target places it among the larger protocols in the corpus, above the 87-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (2844% higher).
The record links to 2 conditions, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 2 interventions - of which Ferric Carboxymaltose (FCM) is the first listed.
NCT00981045 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00981045 about?
NCT00981045 is a clinical study titled "Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function". The primary objective of this study is to examine the efficacy and safety (cardiovascular) of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron sucrose (Venofer) in subjects who have iron deficiency anemia (IDA) and impaired renal function.
What is the current status of trial NCT00981045?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,561 participants. The study started on 2009-08. Estimated completion is 2011-08.
What conditions does trial NCT00981045 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia, Impaired Renal Function.
What interventions are being tested in trial NCT00981045?
The interventions under investigation include: Ferric Carboxymaltose (FCM) (DRUG), Iron Sucrose (Venofer) (DRUG).
Who is sponsoring clinical trial NCT00981045?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00981045 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00981045's enrollment target sits among peer trials
2,561 1st of 24 higher than 24 of 24 other Iron Deficiency Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Iron Deficiency Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
RECRUITING · Phase 3
-
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
RECRUITING · Phase 3
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
-
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
COMPLETED · Phase 3
-
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
COMPLETED · Phase 3
-
Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia